DrugPatentWatch Database Preview
« Back to Dashboard
|NCT01873248||Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients||Recruiting||Jonsson Comprehensive Cancer Center||Phase 1/Phase 2||This is a prospective, Phase 1-2, single center study in a total of 100 subjects with Neuroendocrine Tumors (NETs). Study participants will receive a one-time administration of 68Ga-DOTATATE and undergo a PET/CT imaging study, to investigate its suitability as a PET imaging agent for NETs.|
|NCT01967537||Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors||Recruiting||National Cancer Institute (NCI)||Phase 2||
- Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The
only treatment for NETs is surgery, but most are found when they are too advanced for
surgery. Researchers are looking for the best way to find NETs earlier, so that surgery can
be successful. They want to test if the study drug can be used along with imaging devices to
- To see how well a new experimental imaging agent, 68Gallium-DOTATATE, detects unknown
primary and metastatic NETs in the gastrointestinal system and pancreas.
- Adults over 10 years old with a suspected NET or family history of NET.
- Participants will be screened with a medical history and physical exam, and have a
- Participants will undergo three scans. For all of these, a substance is injected into
their body, they lie on a table, and a machine takes images.
|NCT02078843||Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors||Terminated||SWAN Isotopen AG, Bern||Phase 1/Phase 2||The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.|
Trials by Country
Clinical Trial Phase
Clinical Trial Status